A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)

被引：0
|
作者：
Bekaii-Saab, T. [1 ]
Starodub, A. [2 ,3 ]
El-Rayes, B. [4 ]
O'Neil, B. [5 ]
Shahda, S. [5 ]
Ciombor, K. [6 ]
Noonan, A. [6 ]
Hanna, W. [7 ]
Sehdev, A. [5 ]
Shaib, W. [4 ]
Mikhail, S. [6 ]
Neki, A. [6 ]
Oh, C. [8 ]
Li, Y. Z. [8 ]
Li, W. [8 ]
Borodyansky, L. [8 ]
Li, C. J. [8 ]
机构：
[1] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
[2] IU Hlth Goshen Ctr Canc Care, Goshen, IN USA
[3] Parkview Hlth, Ft Wayne, IN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] IU Hlth Univ Hosp, Indianapolis, IN USA
[6] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Univ Tennessee, Med Ctr, Knoxville, TN USA
[8] Boston Biomed Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA - 002
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    De Jesus-Acosta, Ana
    Sugar, Elizabeth A.
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Rasheed, Zeshaan
    Zheng, Lei
    Begum, Asma
    Anders, Robert
    Maitra, Anirban
    McAllister, Florencia
    Rajeshkumar, N. V.
    Yabuuchi, Shinichi
    de Wilde, Roeland F.
    Batukbhai, Bhavina
    Sahin, Ismet
    Laheru, Daniel A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 498 - 505
  • [33] Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
    Pijnappel, Esther N.
    Wassenaar, Nienke P. M.
    Gurney-Champion, Oliver J.
    Klaassen, Remy
    van der Lee, Koen S.
    Pleunis-van Empel, Marjolein
    Richel, Dick J.
    Legdeur, Marie-Cecile J. C.
    Nederveen, Aart J.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Elizabeth A. Sugar
    Peter J. O’Dwyer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Zeshaan Rasheed
    Lei Zheng
    Asma Begum
    Robert Anders
    Anirban Maitra
    Florencia McAllister
    N. V. Rajeshkumar
    Shinichi Yabuuchi
    Roeland F. de Wilde
    Bhavina Batukbhai
    Ismet Sahin
    Daniel A. Laheru
    British Journal of Cancer, 2020, 122 : 498 - 505
  • [36] A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer.
    Pant, Shubham
    Smaglo, Brandon George
    Huey, Ryan W.
    Haldar, Saurav Daniel
    Morelli, Maria Pia
    Willis, Jason
    Xiao, Lianchun
    Yuan, Ying
    Attanasio, Sergio
    Shah, Rutvi
    Citron, Francesca
    Zhao, Dan
    Kopetz, Scott
    Maitra, Anirban
    Welsch, Dean
    Sheth, Rahul
    Bhosale, Priya
    Wolff, Robert A.
    Viale, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 743 - 743
  • [37] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 659 - 659
  • [39] Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy (Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
    Picozzi, Vincent J.
    Leach, Joseph
    Larson, Tim
    Nishikubo, Carol Y.
    Anthony, Stephen Patrick
    Lin, Bruce S.
    Bolejack, Vanessa
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
    Lim, Kian-Haut
    Hidalgo, Manuel
    O'Hara, Mark H.
    Spencer, Kristen R.
    Garrido-Laguna, Ignacio
    DeNardo, David G.
    Bhambhani, Vijeta
    Patrick, Gloria
    Cheng, Yaofeng
    Coma, Silvia
    Pachter, Jonathan A.
    Denis, Louis J.
    CANCER RESEARCH, 2024, 84 (02)
12345